UK ENcorafenib and BInimetinib Real-world Study in Melanoma

This study, called the UK ENcorafenib and BInimetinib Real-world Study in Melanoma, is designed to learn more about a specific treatment for advanced skin cancer called melanoma. This treatment uses two medicines, encorafenib and binimetinib. It's for people whose melanoma has spread (metastatic) and has a particular genetic change called a BRAF V600 mutation. This genetic change is found in some melanomas and means they might respond to these targeted therapies.

Unlike traditional clinical trials where specific doctors and nurses closely monitor participants, this study observes how these medications are used in everyday NHS care across the UK. We want to see how they perform in a wider group of patients, what challenges people might face, and how the treatment affects their daily lives and overall well-being. This kind of 'real-world' information is very valuable because it can capture experiences that might not be seen in highly controlled clinical trials.

The information gathered will help us understand the treatment's impact on quality of life and give us a clearer picture of its effectiveness and safety outside of a research setting. This study builds on earlier research, called the COLUMBUS trial, which initially showed that encorafenib and binimetinib are effective and safe. Now, we want to add to that knowledge with experiences from people receiving this treatment as part of their routine care.